REG - Polarean Imaging PLC - Promotion & sales representative agreement

Polarean ImagingAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250624:nRSX0359Oa&default-theme=true

RNS Number : 0359O  Polarean Imaging PLC  24 June 2025

Polarean Imaging Plc

("Polarean" or the "Company")

 

Promotion & Sales Representative Agreement

New commercial partnership to accelerate US market growth

Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging
technology leader in functional Magnetic Resonance Imaging ("MRI") of the
lungs, announces that it has signed a Representative Agreement with Ascend
Imaging LLC ("Ascend Imaging"), for the promotion and sale of Polarean
products in specific US states.

 

Under the agreement, Ascend Imaging will act as a non-exclusive, independent
manufacturer's representative in four US states, supporting the promotion and
sale of the Company's Xenon MRI platform. Ascend will complement Polarean's
existing commercial team by identifying new prospective customers, driving
engagement, and supporting the negotiation and closure of sales opportunities.

 

Ascend Imaging specialises in radiology and radiation oncology solutions,
including advanced imaging hardware and artificial intelligence (AI)
technologies. Their team brings deep expertise and long-standing relationships
with healthcare providers across their regions - making them a strong
strategic fit for Polarean's targeted expansion in functional lung imaging.

 

Alan Huang, Ph.D., Vice President of Sales for Polarean, said: "We are pleased
to welcome Ascend Imaging as a strategic sales partner. Their focus on
radiology and radiation oncology, combined with a deep understanding of
imaging workflows and strong customer relationships, aligns well with our
commercial strategy. This partnership enhances our reach in key US regions
while maintaining operational efficiency, and we expect it to support
meaningful commercial momentum in the second half of 2025 and beyond."

 

Wesley Adams, President of Ascend Imaging, said: "We are excited to partner
with Polarean to help bring their groundbreaking Xenon MRI technology to more
healthcare providers. Our experience in radiology and AI solutions, combined
with long-standing customer relationships, positions us well to support
Polarean's mission of revolutionizing pulmonary medicine. We look forward to
expanding access to this important imaging innovation."

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the
European Union (Withdrawal) Act 2018.

 

Enquiries:

 

 Polarean Imaging plc                                          www.polarean.com
                                                               (https://walbrookpr.sharepoint.com/sites/Polarean-WalbrookPR/Shared%20Documents/RNS%20announcements/www.polarean.com)
                                                               / www.polarean-ir.com
                                                               (https://walbrookpr.sharepoint.com/sites/Polarean-WalbrookPR/Shared%20Documents/RNS%20announcements/www.polarean-ir.com)
 Christopher von Jako, Ph.D., Chief Executive Officer                                           Via Walbrook PR

 Charles Osborne, Chief Financial Officer

 Stifel (NOMAD and Sole Corporate Broker)                                                                                        +44 (0)20 7710 7600
 Nicholas Moore / Nick Harland / Brough Ransom / Ben Good

 Walbrook PR            Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
 Anna Dunphy / Paul McManus / Marcus Ulker

 

About Polarean

Polarean is a revenue-generating medical imaging technology company
revolutionising pulmonary medicine through direct visualisation of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimise lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarisation science and has successfully developed the first and only
hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarisation system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform.

 

For the latest news and information about Polarean, please visit
www.polarean.com (http://www.polarean.com) .

 

XENOVIEW® IMPORTANT SAFETY INFORMATION

 

Indication

XENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised
contrast agent indicated for use with magnetic resonance imaging (MRI) for
evaluation of lung ventilation in adults and pediatric patients aged 6 years
and older.

 

Limitations of Use

XENOVIEW has not been evaluated for use with lung perfusion imaging.

 

CONTRAINDICATIONS

None.

 

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen
administered simultaneously with XENOVIEW inhalation can cause degradation of
image quality. For patients on supplemental oxygen, withhold oxygen inhalation
for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.

 

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may
cause transient hypoxemia in susceptible patients. Monitor all patients for
oxygen desaturation and symptoms of hypoxemia and treat as clinically
indicated.

 

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient)
in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse
Reactions in Pediatric and Adolescent Patients: In published literature in
pediatric patients aged 6 to 18, transient adverse reactions were reported:
blood oxygen desaturation, heart rate elevation, numbness, tingling,
dizziness, and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient increase in
heart rate was reported following hyperpolarized xenon Xe 129 administration.
XENOVIEW is not approved for use in pediatric patients less than 12 years of
age.

 

Please see full prescribing information at www.xenoview.net
(http://www.xenoview.net) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRPKNBPQBKDNAB